David Pernock
-
Exton Gene Therapy Developer Fibrocell Science Nears Second New Drug Application
After investing almost $3 million more cash in its operations, including $1 million more than the same quarter a year ago for gene therapy research…
-
Veteran Pharma CFO Stays In Chesco By Joining Fibrocell Team
The Wharton School alumnus and experienced chief financial officer Keith A. Goldan will stick around in Chester County in the wake of a major deal between…
-
Fibrocell Science Appoints New Interim Chief Financial Officer
Kimberly M. Smith is new interim chief financial officer, treasurer and corporate secretary at Fibrocell Science, Inc. David Pernock, Fibrocell’s chairman and CEO, thanked former…
-
Fibrocell Science Rings NASDAQ Bell, Investigates New Drug
Its been a busy week for the people at Fibrocell, the Exton based autologous cell therapy company focused on developing first-in-class treatments for rare and…
-
Fibrocell Share Price Jump Fueled By Insider Buys
What’s going on with Fibrocell Science’s (FCSC) shares? According to Zacks Investment Research, the online research company, shares of the Exton based cell therapy developer rose…
-
Fibrocell Of Exton Reports Strong Start For 2014
Exton based Fibrocell Science, Inc. recently reported its first quarter financials and what the company believes is a strong start for 2014. The company, in…
-
Fibrocell Is Late In Filing 1Q Report
Chester County cell therapy developer Fibrocell Science Inc. of Exton expects to file its first quarter financial report this week after a five-day delay to…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
